SPARCL1在肝癌中的表达及其临床意义

Expression of SPARCL1 in Primary Hepatocellular Carcinoma and Its Clinical Significance

目的探讨SPARCL1表达与肝癌患者术后预后的关系。方法收集154例肝癌患者的术后石蜡切片标本、临床病理资料及随访资料,采用免疫组化染色方法对石蜡切片组织中SPARCL1进行检测。结果不同肝癌组织中SPARCL1的水平具有差异;SPARCL1表达下调与门脉癌栓、病理分化差、TNM分期晚和BCLC分期晚等恶性指标显著相关;SPARCL1表达下调的肝癌患者其中位生存时间显著缩短(40.6个月vs118.7个月,P=0.002)。结论 SPARCL1在肝癌中表达下调,提示肝癌患者的预后不良。

Objective To explore the expression of SPARCL1 in resectable human hepatocellular carcinoma（ HCC） and investigate the clinical role of SPARCL1 in HCC. Methods 154 specimens of HCC patients after resection and their clinicopathological data were collected. The expression levels of SPARCL1 in tumor were detected by immunohistochemistry（ IHC） method.Results The expression level of SPARCL1 in different HCC tissues had difference,and negative expression level of SPARCL1 was closely correlated with portal vein tumor invasion,pathological differentiation,BCLC staging and TNM staging. The overall survival of patients with SPARCL1 negative expression was significantly shorter（ 40. 6 months vs 118. 7 months,P = 0. 002）. Conclusion Negative expression of SPARCL1 predicts bad prognosis in HCC patients.